latest newsRead more...
22
Mar 2019Alexion and Affibody Announce Partnership to Co-Develop Anti-FcRn Affibody® Molecule
Alexion Pharmaceuticals Inc and Affibody AB today announced a partnership to codevelop ABY for rare Immunoglobulin G IgGmediated autoimmune diseases Currently in Phase development ABY is a bivalent antibodymimetic that targets the neonatal Fc receptor FcRn ABY has been specifically designed to combine Affibodys protein…
22
Mar 2019Biologics by McKesson Expands Specialty Pharmacy Capabilities to Serve Patients with Rare and Complex Conditions
Biologics by McKesson continues to expand its capabilities as a specialty pharmacy expert in oncology and complex conditions through a new exclusive distribution agreement After making recent investments to leverage more than years of oncology experience into other complex conditions Biologics has been selected by…
21
Mar 2019Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics
Vivet Therapeutics a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need and Pfizer Inc NYSE PFE announced today that Pfizer has acquired a equity interest in Vivet and secured an exclusive option…
21
Mar 2019Takeda and HemoShear Therapeutics Extend Exclusive Drug Discovery Partnership in Liver Diseases
HemoShear Therapeutics LLC a privately held biotechnology company today announced an extension of its partnership with Takeda Pharmaceutical Company Limited to discover and develop additional novel therapeutics for liver diseases including nonalcoholic steatohepatitis NASH We are excited that Takeda recognizes our unique ability to identify…
press releasesRead more...
22
Mar 2019Lead Pharma Announces Start of Phase I Clinical Trials with SAR441169 Candidate Treatment for Psoriasis
Lead Pharma a pharmaceutical company developing innovative medicines for the treatment of immunological and oncological indications today announced that it has achieved a fourth milestone under its license collaboration agreement…
22
Mar 2019Knopp Biosciences Collaborates with Leading British Researchers to Initiate Phase II Clinical Trial of Dexpramipexole in the Treatment of Severe Eosinophilic Asthma
Knopp Biosciences LLC a private drug discovery and development company dedicated to providing breakthrough treatments for inflammatory and neurological diseases with high unmet medical needs announced today a collaboration with…
22
Mar 2019Primex Pharmaceuticals and Nordic Group Sign a Strategic Partnership to Commercialise OZALIN® in France
Nordic Group a pharmaceutical company focusing on the development and commercialisation of hospital and orphan products and Primex Pharmaceuticals AG an innovative global Anaesthesia pharmaceutical company announced a strategic agreement…
22
Mar 2019Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer's Disease
Biogen and Eisai Co Ltd announced the decision to discontinue the global Phase trials ENGAGE and EMERGE designed to evaluate the efficacy and safety of aducanumab in patients with mild…
22
Mar 2019AlzProtect Starts Collaboration with PAREXEL Biotech for Phase 2a of AZP2006 for the Treatment of Progressive Supranuclear Palsy (PSP)
ALZPROTECT a biopharmaceutical company engaged in the development of drugs for the treatment of Alzheimers disease today announced that PAREXEL Biotech a new division of PAREXEL International Corporation has been…
EventsRead more...
24-27
Mar 201915th Annual Pharma Forum 2019
CBI
New York Marriott Marquis
25-26
Mar 201919th Annual Medicinal & Pharmaceutical Sciences Congress
Conference Series LLC Ltd
Courtyard by Marriott Hong Kong
25-26
Mar 20193rd Product Complaints Forum
ExL Events, Inc.
The Inn at Penn, a Hilton Hotel
25-26
Mar 2019Medical Device Safety & Reporting Summit
ExL Events, Inc.
The Inn at Penn, a Hilton Hotel
TOP ARTICLES
-
1
Mock-up in The Design Stage - FPS’s particular attention
FPS is an Italian company specialised in the production of containment and micronization systems for Pharmaceutical Biotech and Fine Chemical companies In th..
-
2
MicroRNA (miRNA) in Nanostructure Lipid Carriers based Tumor Gene Therapy
Introduction MicroRNAs is a noncoded double stranded RNAs made of approximately of nucleotides disclosed in by Ambros and Ruvkun laboratories that has sign..
-
3
Identification of MicroRNAs and Their Targets in Cancer
Although our cells are well equipped with regulatory checkpoints transformation of normal cells to malignant cancerous cells often occurs as a genetic disease W..
-
4
Are you Ready for EU FMD?
With the deadline looming for enactment of EU FMD and US DSCSA Vikash Pushpraj Senior Vice President rfxcel explains how achieving compliance is about much more..
-
5
Life-style, Environment, and Lack of Prediabetes Diagnosis Fueling Diabetic Epidemic
Introduction For the past ten years ample evidence exists to suggest that what we eat and how we live determines how our body and genes behave A rapid rise i..
-
6
Cancer Stem Cell (CSC) Inhibitors
Cancer as a group of heterogeneous diseases very well known Unimaginable amounts of money and manhours have been spent in finding cure for this deadly disease H..
Knowledge Bank
-
Interviews
Merck
Staff Engineer, Manufacturing Science and Technology, South East Asia
Karen Chan is a process engineer at Merck Pte Ltd Chan has six years of experience in the biopharmaceutical industry and two years of experience in research development She provides technical support in areas such as process development troubleshoot..
-
Articles
Nanomedicines management for advance therapy of NeuroAIDS: State of art
Introduction The Human Immune deficiency Virus HIV infected brain cells through virus or HIV linked oncogenes The major complication of such infection leads to dementia peripheral neuropathies neurosyphilis meningitis etc The development of neuroAIDS still remains a topic of debate due to multifaceted symptom complicated pathology along with lack of precise diagnostic protocol or…
-
Research Insights
Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine
Abstract Background Inflammatory breast cancer IBC is a rare aggressive form of breast cancer associated with HER amplification with high risk of metastasis and an estimated median survival of y We performed an openlabel singlearm phase II clinical trial ClinicalTrialsgov NCT to investigate the efficacy and safety of afatinib an irreversible ErbB family inhibitor alone and in combination with vinorelbine…
-
Case Studies
Rapid, Comprehensive, And Aff Ordable Mycobacterial Diagnosis With Whole-genome Sequencing: A Prospective Case Study
Abstract Background Slow and cumbersome laboratory diagnostics for Mycobacterium tuberculosis complex MTBC risk delayed treatment and poor patient outcomes Wholegenome sequencing WGS could potentially provide a rapid and comprehensive diagnostic solution In this prospective study we compare realtime WGS with routine MTBC diagnostic workflows Methods We compared…
-
Techno Trends
Nottingham University Launches First-of-its-kind Equipment for Chemical Imaging of Materials, Cells & Tissues
The University of Nottingham launched unique firstofitskind equipment DOrbiSIMS which allows labelfree chemical imaging of materials cells and tissues with the potential to transform research in these areas DOrbiSIMS will have applications in a multidisciplinary range of research areas These areas include biomedical implants drug delivery systems developing strategies to tackle antimicrobial resistance organic electronic devices and engineering applications Researchers…
-
White Papers
Launching Global Clinical Trials—best Practices For Efficient And Cost-effective Translations: A Lionsbridge White Paper
Summary The target market for conducting global clinical trials has changed significantly moving beyond pharmaceutical early adopters to the mainstream marketplace This shift has placed a heightened focus on the language challenges and complexity of running a global clinical trial More and more companies are moving toward ascending regions such as India and China to…
Advisory Board
Editorial Section
-
Strategy
WAYS TO CREATE MORE AND MORE CONSISTENT PERFORMERS
For all pharma businesses it is a challenge to enable their field forceSales and Marketingto be consistent performers The success or failure in this direction will accordingly decide the fate of the organisations Even if an organisation has highly innovative…
-
Research development
New and Novel Drug Delivery Technologies
By infusing drugs with new and innovative therapeutic benefits drug delivery systems extend products profitable lifecycle giving pharmaceutical companies competitive and financial advantages and providing patients with improved medications Formulation development is being used in the creation of new dosage…
-
Clinical Trials
ELIXIR FOR SOURCING AND RETAINING CANDIDATES
Many pharma companies have been suffering silently from shortage of suitable candidates to fill up vacancies in the field and also of high attrition rate leading to terrible but avoidable loss of business due to vacancies In this article lets…
-
Manufacturing
CLINICAL MANUFACTURING ON TIME AND WITHIN BUDGET
In a record submitted drugs received approval from the American regulatory agency FDA One of the reasons for this success is the reciprocal commitment between the sponsor and regulatory bodies to maintain a high quality…
-
Information Technology
Creating Better Clean Label Soft Gels Without Gelatin Crosslinking
Modern manufacturers are facing to produce the perfect clean label soft gel Crosslinking is a common reaction in gelatin capsules with a direct impact on APIs bio availability and opening time Modern technology offers a…
-
Expert Talk
The Pharmaceutical Supply Chain from a CDMO’s Perspective
In the world of drug manufacturing change is a constant In order to be successful Contract Development and Manufacturing Organisations CDMOs must remain flexible anticipating and adjusting to market dynamics as necessary This ability to…
